Ultime notizie per Galera Therapeutics (OTC:GRTX) Azioni

Galera Therapeutics

Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

GALERA THERAPEUTICS INC by Galera Therapeutics, Inc.

Galera Therapeutics Inc

WIIM

Tempus AI shares are trading lower after the company reported mixed Q3 financial results. Also, the company announced it entered into an agreement to acquire Ambry Genetics.

Barclays analyst Tom O'Malley maintains Cirrus Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) with a Equal-Weight and lowers the price target from $120 to $105.

News

Price Target

Analyst Ratings

CRUS

Barclays Maintains Equal-Weight on Cirrus Logic, Lowers Price Target to $105

Fabrinet shares are trading lower. The company reported Q1 financial results.

With election day underway, prediction markets Polymarket and Kalshi are showing divergent odds for Kamala Harris and Donald Trump as major politics traders have placed their bets <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41717129/polymarkets-all-time-leading-trader-bets-over-500-000-on-kamala-harris-slams-nate-silver-f">on the Vice President</a>.
What Happened: Kamala Harris&#8217;s odds of winning the presidency stand at 41% on Kalshi, compared to 38.4% on Polymarket at the time of writing. The spread between the two platforms was as big as 6% in the early morning U.S. Eastern time. Kalshi <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41583301/kalshi-ceo-tarek-mansour-on-the-growing-election-betting-market-a-coin-flip-with-a-bias">has a license</a> from the Commodity Futures Trading Commission (CFTC) to list election-related trading contracts.
The top three traders on Polymarket have all sided with the Vice President to win the election.
<ul>
<li>Veteran trader Domer has <a href="https://polymarket.com/profile/0x9d84ce0306f8551e02efef1680475fc0f1dc1344">wagered</a> $224,344 on Harris winning the electoral college, $147,766 on a Democrat taking both the popular vote and Presidency and $164,884 on a Democrat winning the state of Pennsylvania. In a post on X, the all-time leading trader on the platform <a href="https://x.com/Domahhhh/status/1853086999873196202">cited</a> his estimate of Kamala Harris&#8217;s chances to win the election around 55-60%.</li>
<li>The second trader on Polymarket&#8217;s all-time ranking, Rueben, <a href="https://polymarket.com/profile/0x3cf3e8d5427aed066a7a5926980600f6c3cf87b3">bet</a> over $300,000 on the Vice President to win the popular vote, the electoral college and the Democratic Party to win the Presidency and the House but lose control of the Senate. However, the trader also has a roughly $50,000 stake on the GOP to win the electoral college but lose the popular vote., with a total profit of $1.6 million <a href="https://polymarket.com/profile/0x3cf3e8d5427aed066a7a5926980600f6c3cf87b3">recorded</a> in his portfolio.</li>
<li>Third-placed trader YatSen <a href="https://polymarket.com/profile/0x5bffcf561bcae83af680ad600cb99f1184d6ffbe">bet</a> $172,810 on a Democratic win in the popular vote and presidency, and $57,622 on Harris. The trader also has over $120,000 staked on an electoral college/popular vote split where Trump wins the presidency.</li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
What&#8217;s Next: The influence of prediction markets is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41720318/bitcoin-on-the-evening-of-the-election-heres-how-it-performed-in-2012-2016-and-2020">Bitcoin On The Evening Of The Election—Here&#8217;s How It Performed In 2012, 2016 And 2020</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Kamala Harris Backed By Polymarket's Top 3 All-Time Traders, But Two Of Them Have Hedged Their Bets

Macro Economic Events

Econ #s

Economics

USA Redbook (YoY) 6.0%; 5.6% Prior

Timken shares are trading lower after the company reported mixed Q3 financial results and cut its fY24 adjusted EPS guidance below estimates.

ITUB

Itau Unibanco Holding shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Barclays analyst Lauren Lieberman maintains Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) with a Underweight and lowers the price target from $86 to $85.

Barclays Maintains Underweight on Church & Dwight Co, Lowers Price Target to $85

Guidance

Restaurant Brands International Executive Says Expect FY System-Wide Sales Growth Will Come In Slightly Below Expectations Laid Out In August; In China, Actively Working To Find Right Long-Term Path For Burger King

Barclays analyst Anthony Powell maintains Choice Hotels Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>) with a Underweight and raises the price target from $112 to $123.

Barclays Maintains Underweight on Choice Hotels Intl, Raises Price Target to $123

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/11/04/final-trades-starbucks-freeport-mcmoran-constellation-energy-and-the-xlu.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management said he is keeping an eye on Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>). The stock is expected to make another run at $100, he added.
On Oct. 30, Starbucks reported weaker-than-expected fourth-quarter results. The company posted quarterly earnings of 80 cents per share which missed the analyst consensus estimate of $1.03 per share. The company reported quarterly sales of $9.074 billion which missed the analyst consensus <a href="https://www.benzinga.com/news/earnings/24/10/41634203/starbucks-likely-to-report-lower-quarterly-earnings-these-most-accurate-analysts-revise-forecasts-a">estimate of $9.375 billion.</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Shannon Saccocia of NB Private Wealth named The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) as <a href="https://www.benzinga.com/quote/XLU">her final trade.</a>
Sarat Sethi of DCLA named Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) as his final trade.
On Oct. 22, Freeport-McMoRan reported third-quarter FY24 results. Revenue stood at $6.79 billion, beating the consensus of $6.47 billion. Copper sales totaled 1.0 billion pounds, down 7% Y/Y and 2% above the July 2024 estimate, due to the timing of shipments and lower ore grades and operating rates in North America.
Joseph M. Terranova of Virtus Investment Partners picked Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>), which pulled back on Monday.
On Nov. 4, Constellation Energy reported third-quarter results and revised its FY24 adjusted EPS guidance, which is below estimates.
Price Action:
<ul>
<li>The Utilities Select Sector SPDR Fund fell 1.2% during Monday's session.</li>
<li>Starbucks shares fell 1.9% to settle at $97.03 during Monday's session.</li>
<li>Freeport-McMoRan shares gained 1.5% to close at $46.27 on Monday.</li>
<li>Constellation Energy shares fell 12.5% to settle at $225.95 on Monday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713185/top-4-tech-and-telecom-stocks-that-may-collapse-this-month">Top 4 Tech And Telecom Stocks That May Collapse This Month</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

Trading Ideas

SBUX

Starbucks, Freeport-McMoRan, Constellation Energy And More On CNBC's 'Final Trades'

Qualigen Therapeutics, Inc. - Common Stock

QLGN

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Barclays analyst Michael Leithead maintains Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) with a Equal-Weight and raises the price target from $21 to $23.

Barclays Maintains Equal-Weight on Chemours, Raises Price Target to $23

<a href="https://www.benzinga.com/topic/2024-election">Election Day has arrived</a>, and we could all probably use a deep breath. Take a moment if you need it.
Now, onto the cannabis front where voters in Nebraska, North Dakota, South Dakota and Florida <a href="https://www.benzinga.com/markets/cannabis/24/10/41387752/winding-road-to-cannabis-legalization-ahead-for-4-states-set-to-vote-in-2024-what-do-the-polls-s">will decide on ballot initiatives</a> to legalize marijuana for recreational or medical use. If approved, these states will join the 38 others that have embraced some form of cannabis legalization and join the rapidly changing landscape of <a href="https://www.benzinga.com/topic/cannabis-reform">marijuana policy</a> in the U.S.
Here's what&#8217;s changed in the landscape…some might even say drastically.
<h3 class="wp-block-heading">One Of Our Favorites: Adult Weed Consumption Rises As Teen Use Falls</h3>
Concerns over a spike in youth cannabis consumption following early legalization efforts, beginning with Colorado and Washington in 2012, have proven unfounded. Contrary to fears, marijuana use among teens has declined, or maybe never really took off.
From 2011 to 2021, the <a href="https://www.benzinga.com/topic/cannabis-reform">percentage of adolescents reporting marijuana use</a> dropped from 23% to under 16%.
"The ‘sky's going to fall' scenario was that all of the kids were just going to have access to all of the cannabis and it was going to be a terrible, terrible thing," said Ryan Vandrey, professor of psychiatry and behavioral sciences at Johns Hopkins Medicine who studies cannabis.
"It just goes to show that teenagers will do exactly the opposite of what you think they're going to do at all times," Vandrey <a href="https://www.nytimes.com/2024/11/04/well/weed-cannabis-america.html">told</a> The New York Times, confirming what every parent who has or is raising a teenager already knows.
Adult cannabis consumption, meanwhile, <a href="https://www.benzinga.com/markets/cannabis/24/08/40652731/cannabis-and-hallucinogen-consumption-hit-all-time-highs-in-2023-while-tobacco-and-alcohol-decli">has reached historic highs</a>, with 42% of individuals aged 19-30 and 29% of those aged 35-50 reporting use in the past year.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41609840/sharp-drop-in-teen-marijuana-use-legalization-and-demographics-examined">Sharp Drop In Teen Marijuana Use: Legalization And Demographics Examined</a>
<h3 class="wp-block-heading">Cannabis Use Surpasses Alcohol</h3>
Yeah, you read that right. Recent studies have show that more Americans are now consuming <a href="https://www.benzinga.com/markets/cannabis/24/05/38976556/daily-cannabis-consumption-outpaces-daily-alcohol-use-in-the-us-for-the-first-time-new-study-sho">weed daily rather than alcohol</a>. Nearly 18 million people report daily or near-daily marijuana use, outpacing the 15 million who drink with similar frequency. 
<h3 class="wp-block-heading">Seniors Jump On The Weed Wagon Because…Why Not?</h3>
The country&#8217;s 73 million baby boomers are among the&nbsp;<a href="https://www.benzinga.com/markets/cannabis/23/08/33583433/baby-boomers-turning-to-weed-en-masse-say-it-improves-memory-and-mood-doctors-agree-cnn-series-e" target="_blank" rel="noreferrer noopener">fastest-growing demographic</a><a href="https://www.benzinga.com/markets/cannabis/24/01/36458087/senior-cannabis-consumers-balancing-act-relief-for-numerous-conditions-comes-with-warnings-but-w" target="_blank" rel="noreferrer noopener">&nbsp;</a>of&nbsp;cannabis users in the U.S. and around the world. In the past 8 years, senior cannabis consumption has tripled. Seniors also happen to&nbsp;possess&nbsp;half of the nation's&nbsp;$140 trillion&nbsp;in wealth, so they&#8217;re helping the economy even after they&#8217;ve retired.
<h3 class="wp-block-heading">Closing That Gender Gap </h3>
Cannabis use has long been more prevalent among men than women, but that disparity is shrinking. In 2023, young women (ages 19-30) <a href="https://www.benzinga.com/markets/cannabis/24/08/40652731/cannabis-and-hallucinogen-consumption-hit-all-time-highs-in-2023-while-tobacco-and-alcohol-decli">reported higher rates of cannabis use</a> than their male counterparts. Teenage girls also now report higher marijuana use than boys, marking a shift in gender patterns of cannabis consumption.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41726320/hemp-donations-fuel-desantis-and-florida-gops-charge-against-weed-legalization-new-findings">Hemp Donations Fuel DeSantis And Florida GOP&#8217;s Charge Against Weed Legalization, New Findings</a></li>
</ul>
Photo: Shutterstock

Cannabis

Government

Politics

Legal

Election Day 2024: Will Florida, Nebraska, North And South Dakota Join The Marijuana Revolution?

Barclays analyst Tom O'Malley maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Overweight and raises the price target from $70 to $87.

ALAB

Barclays Maintains Overweight on Astera Labs, Raises Price Target to $87

Barclays analyst Julian Mitchell maintains APi Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APG#NYSE">APG</a>) with a Overweight and raises the price target from $43 to $44.

Barclays Maintains Overweight on APi Gr, Raises Price Target to $44

KITT

Nauticus Robotics Secures Agreement To Convert $33M Debt Into Equity Via Preferred Stock Exchange, Aiming To Deleverage Balance Sheet And Address Nasdaq Compliance

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Ceva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NYSE">CEVA</a>) is &#8220;way too high, and I think you <a href="https://www.benzinga.com/quote/CEVA">should take something off the table.&#8221;</a>
Ceva will announce results for the third quarter on Nov. 7, 2024, before the opening bell.
&#8220;I love space stuff, and that's why I keep recommending Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>),&#8221; Cramer said when asked about Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>). If there's going to be something in space, it is going to be done by Elon Musk."
Intuitive Machines will release its financial results for the third quarter on Thursday, Nov. 14, before the market opens.
When asked about Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), &#8220;I want so badly for the company to do well, but I can't recommend the stock.&#8221;
The company is reportedly set to pause production of its F-150 Lightning from mid-November until the year&#8217;s end, citing weaker-than-anticipated demand for the electric pickup, Automotive News reported.
&#8220;They are in the oil service business, and oil is not a growth commodity. So, I'm going to say you can't own the stock here, as much as I really like them,&#8221; the &#8220;Mad Money&#8221; host said when asked about SLB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>).
The company, last week, disclosed that its OneSubsea joint venture won a contract from BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) for a subsea boosting system as part of the greenfield development of the Kaskida project in the deepwater U.S.
Cramer recommended taking something off the table, when asked about Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>).
Vistra will replace The AES Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) in the Dow Jones Utility Average, effective prior to the open of trading on Friday, Nov. 8.
Price Action:
<ul>
<li>CEVA shares fell 0.2% to settle at $23.64 on Monday.</li>
<li>Intuitive Machines shares fell 6.5% to close at $7.58 on Monday.</li>
<li>Ford shares gained 1.4% to settle at $10.36 during the session.</li>
<li>SLB gained 1.4% to settle at $40.32 on Monday.</li>
<li>Vistra shares fell 3.2% to close at $115.74.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713185/top-4-tech-and-telecom-stocks-that-may-collapse-this-month">Top 4 Tech And Telecom Stocks That May Collapse This Month</a></li>
</ul>

CEVA

LUNR

TSLA

Jim Cramer Says He Can't Recommend This Major Automaker, Ceva Is 'Way Too High'

DuPont shares are trading higher after the company reported better-than-expected Q3 EPS and raised its FY24 adjusted EPS guidance.

APLS

Apellis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.

Galera Therapeutics GAAP EPS of -$0.10

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Wednesday!



Moving stocks this morning are earnings reports, acquisition plans, new drug data and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>INVO Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is rocketing more than 55% alongside its <a href="https://finance.yahoo.com/news/invo-reports-fourth-quarter-full-205900118.html">Q4 earnings report</a>.</li>



<li>Vanda Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/vnda-stock-quote/">VNDA</a>) shares are soaring over 38% on <a href="https://www.nasdaq.com/press-release/future-pak-confirms-proposal-to-acquire-vanda-pharmaceuticals-for-%247.25-to-%247.75-per">a firm acquisition proposal</a>.</li>



<li>VIA Optronics (NYSE:<a href="https://investorplace.com/stock-quotes/viao-stock-quote/">VIAO</a>) stock is surging more than 32% with heavy pre-market trading.</li>



<li>Clene (NASDAQ:<a href="https://investorplace.com/stock-quotes/clnn-stock-quote/">CLNN</a>) shares are rising over 26% on <a href="https://seekingalpha.com/news/4090283-clene-stock-rallies-post-market-on-ms-drug-data?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain%7Csection%3Aon-the-move">new drug data</a>.</li>



<li>Chromocell Therapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/chro-stock-quote/">CHRO</a>) stock is gaining more than 26% on an update to a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239123&amp;type=PDF&amp;symbol=CHRO&amp;cdn=722216dc7f57070dff83767fe9648f9d&amp;companyName=Chromocell+Therapeutics+Corporation&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-04-17">secondary stock offering</a>.</li>



<li>CXApp (NASDAQ:<a href="https://investorplace.com/stock-quotes/cxai-stock-quote/">CXAI</a>) shares are increasing over 26% with its <a href="https://www.marketwatch.com/story/cxapp-shares-rise-29-on-4q-2023-annual-recurring-revenue-growth-13f8abea">latest earnings report</a>.</li>



<li>Seelos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/seel-stock-quote/">SEEL</a>) stock is climbing more than 24% without any clear news on Wednesday morning.</li>



<li>Mobile Global Esports (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgam-stock-quote/">MGAM</a>) shares are getting a 22% boost as it <a href="https://investorplace.com/2024/04/why-is-mobile-global-esports-mgam-stock-down-18-today/">prepares for delisting</a>.</li>



<li>Gamer Pakistan (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/">GPAK</a>) stock is jumping 21% despite a lack of news today.</li>



<li>Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) shares are up over 19% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238318&amp;type=PDF&amp;symbol=GRTX&amp;cdn=6788b7c94daccbdc9a6c5412e270d44c&amp;companyName=Galera+Therapeutics+Inc.&amp;formType=SC+13G&amp;formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-04-16">shareholder stake update</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Trilogy Metals (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tmq-stock-quote/">TMQ</a>) stock is plummeting more than 22% <a href="https://www.nasdaq.com/press-release/trilogy-metals-provides-update-on-the-ambler-access-project-2024-04-17">following an update</a> to its Ambler Access Project.</li>



<li>Trio Petroleum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tpet-stock-quote/">TPET</a>) shares are diving over 20% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239194&amp;type=PDF&amp;symbol=TPET&amp;cdn=fb7a5495a316777660288b1087458323&amp;companyName=Trio+Petroleum+Corp.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-17">securing senior notes and a purchase agreement</a>.</li>



<li>Connexa Sports Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/yyai-stock-quote/">YYAI</a>) stock is tumbling more than 18% on Wednesday morning.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) shares are taking a close to 18% beating following a rally yesterday.</li>



<li>Ontrak (NASDAQ:<a href="https://investorplace.com/stock-quotes/otrk-stock-quote/">OTRK</a>) stock is sliding over 16% with the release of its <a href="https://finance.yahoo.com/news/ontrak-announces-2023-fourth-quarter-200500612.html">Q4 2023 earnings report</a>.</li>



<li>Dragonfly Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/dfli-stock-quote/">DFLI</a>) shares are retreating more than 16% <a href="https://investorplace.com/2024/04/why-is-dragonfly-energy-dfli-stock-up-56-today/">after rallying yesterday</a>.</li>



<li>Dynatronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/">DYNT</a>) stock is pulling back over 16% <a href="https://investorplace.com/2024/04/why-is-dynatronics-dynt-stock-up-93-today/">after rising on Tuesday</a>.</li>



<li>Ryvyl (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvyl-stock-quote/">RVYL</a>) shares are still falling more than 15% despite <a href="https://www.nasdaq.com/press-release/ryvyl-inc.-announces-cancellation-of-proposed-underwritten-public-offering-2024-04-16">canceling a proposed public offering</a>.</li>



<li>Hub Cyber Security (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/">HUBC</a>) stock is dropping over 14% <a href="https://investorplace.com/2024/04/why-is-hub-cyber-security-hubc-stock-up-35-today/">after a rally yesterday</a>.</li>



<li>iSun (NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/">ISUN</a>) shares close out our pre-market stock movers down more than 13% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238741&amp;type=PDF&amp;symbol=ISUN&amp;cdn=82f25393dbc89b776256155c3f0856b7&amp;companyName=iSun+Inc.&amp;formType=10-K&amp;formDescription=Annual+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-16">on an investor update</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-april-17th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the trading week with a look at the biggest pre-market stock movers for Monday morning!



Moving stocks this morning are earnings, investments, a delisting and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Moolec Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlec-stock-quote/">MLEC</a>) stock is rocketing more than 67% on approval for its <a href="https://www.nasdaq.com/press-release/moolec-becomes-first-molecular-farming-company-to-achieve-usda-approval-for-plant">plant-groan animal proteins</a>.</li>



<li>OLB Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/">OLB</a>) shares are soaring over 46% with heavy pre-market trading.</li>



<li>Complete Solaria (NASDAQ:<a href="https://investorplace.com/stock-quotes/cslr-stock-quote/">CSLR</a>) stock is surging more than 42% <a href="https://www.nasdaq.com/press-release/retail-stock-sector-and-chairman-t.j.-rodgers-invest-in-complete-solaria-2024-04-21">on investment news</a>.</li>



<li>SuperCom (NASDAQ:<a href="https://investorplace.com/stock-quotes/spcb-stock-quote/">SPCB</a>) shares are gaining over 33% ahead of its <a href="https://www.nasdaq.com/press-release/supercom-to-report-fourth-quarter-and-full-year-2023-financial-results-on-april-22">Q4 2023 earnings report</a> this morning.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rising more than 18% on Monday morning.</li>



<li>Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) shares are increasing over 17% without any clear news this morning.</li>



<li>Palisade Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pali-stock-quote/">PALI</a>) stock is climbing more than 16% despite a lack of news today.</li>



<li>Global Gas (NASDAQ:<a href="https://investorplace.com/stock-quotes/hgas-stock-quote/">HGAS</a>) shares are heading over 14% higher on Monday.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is jumping more than 13% on Monday morning.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) shares are up over 13% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Vaxxinity (NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/">VAXX</a>) stock is crashing more than 55% on the company&rsquo;s <a href="https://finance.yahoo.com/news/vaxxinity-announces-intention-voluntarily-delist-202700884.html">plans to delist its shares</a>.</li>



<li>EzFill (NASDAQ:<a href="https://investorplace.com/stock-quotes/ezfl-stock-quote/">EZFL</a>) shares are plummeting close to 37% this morning.</li>



<li>Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) stock is diving over 29% on plans to <a href="https://www.nasdaq.com/press-release/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial">wind down a clinical trial</a>.</li>



<li>iLearningEngines (NASDAQ:<a href="https://investorplace.com/stock-quotes/aile-stock-quote/">AILE</a>) shares are tumbling more than 21% after <a href="https://finance.yahoo.com/news/ilearningengines-inc-becomes-publicly-traded-200500132.html">going public last week</a>.</li>



<li>Redwoods Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/rwod-stock-quote/">RWOD</a>) stock is taking an over 15% beating <a href="https://investorplace.com/2024/04/why-is-redwoods-acquisition-rwod-stock-up-72-today/">after a recent rally</a>.</li>



<li>Biophytis (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpts-stock-quote/">BPTS</a>) shares are sliding more than 15% ahead of <a href="https://www.nasdaq.com/press-release/biophytis-announces-ratio-change-under-its-american-depositary-receipt-adr-program-0">a ratio change tomorrow</a>.</li>



<li>Adlai Nortye (NASDAQ:<a href="https://investorplace.com/stock-quotes/anl-stock-quote/">ANL</a>) stock is dropping nearly 15% today.</li>



<li>BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) shares are falling over 13% this morning.</li>



<li>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) stock is decreasing more than 12% today.</li>



<li>Indonesia Energy (NYSEMKT:<a href="https://investorplace.com/stock-quotes/indo-stock-quote/">INDO</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-april-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Galera Therapeutics (GRTX) has issued an update. Galera Therapeutics, Inc. has implemented a stockholder rights plan, issuing one Right per common ...

Galera Therapeutics Enacts Plan to Deter Hostile Takeovers

Galera Therapeutics GAAP EPS of -$0.08

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) just reported results for the first quarter of 2024.<ul><li>Galera Therapeutics reported earnings per share of -8 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/grtx-stock-earnings-galera-therapeutics-for-q1-of-2024/">GRTX Stock Earnings: Galera Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GRTX Stock Earnings: Galera Therapeutics Reported Results for Q1 2024

Galera Therapeutics (GRTX) has provided an update. Galera Therapeutics, Inc. is streamlining its operations amidst a strategic review by eliminatin...

Galera Therapeutics Restructures Leadership and Cuts Costs

Galera Therapeutics (GRTX) just unveiled an announcement. Galera Therapeutics, Inc. recently settled a lawsuit against two Clinical Research Organi...

Galera Therapeutics Settles Clinical Trial Dispute Lawsuit

Galera Therapeutics (GRTX) has shared an update. Galera is set to dissolve and wind up its business, a decision made by the Board to benefit the sh...

Galera Therapeutics Announces Wind-Up and Special Stockholder Meeting

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) just reported results for the second quarter of 2024.<ul><li>Galera Therapeutics reported earnings per share of -7 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/grtx-stock-earnings-galera-therapeutics-for-q2-of-2024/">GRTX Stock Earnings: Galera Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GRTX Stock Earnings: Galera Therapeutics Reported Results for Q2 2024

AILE

BPTS

BSGM

CHRO

CLNN

CSLR

CXAI

DFLI

DRMA

DXYZ

DYNT

EZFL

GPAK

GRTX

HEPA

HGAS

HUBC

INDO

INVO

ISUN

MGAM

MLEC

OTRK

PALI

PRTG

RVYL

RWOD

SBFM

SEEL

SOAR

SPCB

TPET

VAXX

VIAO

VNDA

YYAI

Biotech

Earnings

Press Releases

General

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

Galera Adopts Limited Duration Stockholder Rights Agreement

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

Comments

Galera Therapeutics

Notizie

Ultime notizie per Galera Therapeutics (OTC:GRTX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO